Generation and characterization of a panel of monoclonal antibodies specific for human fibroblast growth factor receptor 4 (FGFR4)

Hybridoma

Volumn 24, Issue 3, 2005, Pages 152-159

  Chen, Chaoyuan ^a,b   Patel, Sima ^a   Corisdeo, Susanne ^a   Liu, Xiangdong ^a   Micolochick, Holly ^a   Xue, Jiyang ^a   Yang, Qifeng ^a   Lei, Ying ^a   Wang, Baiyang ^a   Soltis, Daniel ^a  

^a Purdue Pharma Discovery Research   (United States)

^b SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FGFR4 MONOCLONAL ANTIBODY; FIBROBLAST GROWTH FACTOR RECEPTOR 4; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BREAST TUMOR; CANCER CELL CULTURE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUSION; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; DRUG ANALYSIS; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNIZATION; IMMUNOGENICITY; LYMPH NODE CELL; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; TISSUE REPAIR;

ANIMALIA; MURINAE;

EID: 20844440557     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2005.24.152     Document Type: Article

References (31)

1. Jaye M, Schlessinger J, and Dionne CA: Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta 1992;1135:185-199.
2. Powers CJ, McLeskey SW, and Wellstein A: Fibroblast growth factors, their receptors and signaling. Endocrinol Relat Cancer 2000;7:165-197.
3. Lee PL, Johnson DE, Cousens LS, Fried VA, and Williams LT: Purification and complementary DNA cloning of a receptor for basic fibroblast growth factor. Science 1989;245:57-60.
4. Bateman A, and Chothia C: Outline structures for the extracellular domains of the fibroblast growth factor receptors. Nat Struct Biol 1995;2:1068-1074.
5. Wang F, Ran M, Xu J, Yan G, and McKeehan WL: Ligand-specific structural domains in the fibroblast growth factor receptor. J Biol Chem 1995;270:10222-10230.
6. Green PJ, Walsh FS, and Doherty P: Promiscuity of fibroblast growth factor receptors. Bioessays 1996;18:639-646.
7. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, and Goldfarb M: Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996;271:15292-15297.
8. Vainikka S, Partanen J, Bellosta P, Coulier F, Birnbaum D, Basilico C, Jaye M, and Alitalo K: Fibroblast growth factor receptor-4 shows novel features in genomic structure, ligand binding and signal transduction. EMBO J 1992:11:4273-4280.
9. Xie MH, Holcomb, I Deuel B, Dowd P, Huang A, Vagts A, Foster J, Liang J, Brush, J Gu, Q Hillan, K, Goddard A, and Gurney AL: FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999;11:729-735.
10. Harmer NJ, Pellegrini L, Chirgadze D, Fernandez-Recio J, and Blundell TL: The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 2004;43: 629-640.
11. Vainikka S, Joukov V, Wennstrom S, Bergman M, Pelicci PG, and Alitalo K: Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). Comparison with FGFR-1. J Biol Chem 1994;269:18320-18326.
12. Morimoto Y, Ozaki T, Ouchida M, Umehara N, Ohata N, Yoshida A, Shimizu K, and Inoue H: Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 2003; 98:2245-2250.
13. Jaakkola S, Salmikangas P, Nylund S, Partanen J, Armstrong E, Pyrhonen S, Lehtovirta P, and Nevanlinna H: Amplification of fgfr4 gene in human breast and gynecological cancers. Int J Cancer 1993;54:378-382.
14. Penault-Llorca F, Bertucci F, Adelaide J, Pare P, Coulier F, Jacquemier J, Birnbaum D, and deLapeyriere O: Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer 1995;61:170-176.
15. La Rosa S, Sessa F, Colombo L, Tibiletti MG, Furlan D, and Capella C: Expression of acidic fibroblast growth factor (aFGF) and fibroblast growth factor receptor 4 (FGFR4) in breast fibroadenomas. J Clin Pathol 2001;54:37-41.
16. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Muller S, Gartner S, Sures I, Wang H, Imyanitov E, Haring H, Knayzev P, Iacobelli S, Hofler H, and Ullrich A: Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002;62:840-847.
17. La Rosa S, Uccella S, Erba S, Capella C, and Sessa F: Immunohistochemical detection of fibroblast growth factor receptors in normal endocrine cells and related tumors of the digestive system. Appl Immunohistochem Mol Morphol 2001;9:319-328.
18. Shah RN, Ibbitt JC, Alitalo K, and Hurst H: FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1alpha. Oncogene 2002;21:8251-8261.
19. Tuominen H, Heikinheimo P, Loo BM, Kataja K, Oker-Blom C, Uutela M, Jalkanen M, and Goldman A: Expression and glycosylation studies of human FGF receptor 4. Protein Expr Purif 2001;21:275-285.
20. Kilpatrick KE, Wring SA, Walker DH, Macklin MD, Payne JA, Su JL, Champion BR, Caterson B, and McIntyre GD: Rapid development of affinity matured monoclonal antibodies using RIMMS. Hybridoma 1997;16:381-389.
21. Kilpatrick KE, Cutler T, Whitehorn E, Drape RJ, Macklin MD, Witherspoon SM, Singer S, and Hutchins JT: Gene gun delivered DNA-based immunizations mediate rapid production of murine monoclonal antibodies to the Flt-3 receptor. Hybridoma 1998; 17:569-576.
22. Kilpatrick KE, Danger DP, Hull-Ryde EA, and Dallas W: High-affinity monoclonal antibodies to PED/PEA-15 generated using 5 μg of DNA. Hybridoma 2000;19:297-302.
23. Kinch, MS, Kilpatrick, KE, and Zhong, C: Identification of tyrosine phosphorylated adhesion proteins in human cancer cells. Hybridoma 1998;17:227-235.
24. Bynum, J, Andrews, JL, Ellis, B, Kull, FC Jr, Austin, EA, and Kilpatrick, KE: Development of class-switched, affinity-matured monoclonal antibodies following a 7-day immunization schedule. Hybridoma 1999;18:407-411.
25. McLeskey SW, Ding IY, Lippman ME, and Kern FG: MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands. Cancer Res 1994;54:523-530.
26. Larocca D, Witte A, Gonzalez AM, and Houston LL: Establishment of epitope-defined monoclonal antibodies with specificity for fibroblast growth factor receptor types 1 and 2. Hybridoma 1998;17:21-31.
27. Laver WG, Air GM, Webster RG, and Smith-Gill SJ: Epitopes on protein antigens: misconceptions and realities. Cell 1990;61: 553-556.
28. rd ed. Academic Press, San Diego, 1996.
29. Alligood KJ, Milla M, Rhodes N, Ellis B, Kilpatrick KE, Lee A, Gilmer TM, and Lansing TJ: Monoclonal antibodies generated against recombinant ATM support kinase activity. Hybridoma 2000;19:317-321.
30. Lindley KM, Su JL, Hodges PK, Wisely GB, Bledsoe RK, Condreay JP, Winegar DA, Hutchins JT, and Kost TA: Production of monoclonal antibodies using recombinant baculovirus displaying gp64-fusion proteins. J Immunol Methods 2000;234:123-135.
31. Chen C, Yang Q, Patel S, Lei Y, McAleer L, Singleton J, Soltis SA, and Wang B: Characterization of human tissue factor (TF)-specific monoclonal antibodies prepared using a rapid immunization protocol. Hybridoma 2005;24:79-86.